

# An open label study to investigate the safety and efficacy of treatment with ACH-0143102 and sofosbuvir in hepatitis C patients

ACTRN12614000307606

---

Status	COMPLETED
Phase	Phase 2
Sponsor	Achillion Pharmaceuticals, Inc
Enrollment	36 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- Chronic HCV infection
- HCV GT-1
- HCV RNA greater than 10,000 IU/mL at screening
- Signed and dated written consent
- Treatment naive subjects

... and 1 more (see full listing online)

### Exclusion (7)

- BMI greater than 36kg/m<sup>2</sup>
- Pregnant or lactating females. Men whose female partners are pregnant or contemplating pregnancy
- Clinically significant laboratory abnormality at screening
- Known HIV infection
- Positive hepatitis B surface antigen

... and 2 more (see full listing online)

## Locations (1 total)

---

Auckland, New Zealand